Xiidra vs Syfovre
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Xiidra | US Syfovre | |
|---|---|---|
| Generic name | lifitegrast | pegcetacoplan |
| Drug class | LFA-1 Antagonist (Eye Drop) | Complement C3 Inhibitor |
| Treats | Dry eye disease | Geographic atrophy (advanced dry AMD) |
| Category | Eye Health | Eye Health |
| Manufacturer | Bausch + Lomb | Apellis Pharmaceuticals |
| Year approved | 2016 | 2023 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $150M | — |
| Common side effects | Eye irritation, Unusual taste, Blurred vision, Eye discomfort on application | Eye discomfort, Floaters, Bleeding in the eye, Increased eye pressure |
Frequently asked questions
Is Xiidra or Syfovre better?
Neither is universally "better." Xiidra (lifitegrast) and Syfovre (pegcetacoplan) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Xiidra and Syfovre?
Xiidra is a LFA-1 Antagonist (Eye Drop) made by Bausch + Lomb, while Syfovre is a Complement C3 Inhibitor made by Apellis Pharmaceuticals. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Xiidra has the larger estimated TV advertising budget of the two.